A Randomized, Double-Blind, Placebo-Controlled, Three-Arm, Parallel-Group, Multicenter, Multinational Safety and Efficacy Trial of 300 mg and 900 mg of Abetimus Sodium in Systemic Lupus Erythematosus (SLE) Patients With a History of Renal Disease
Latest Information Update: 09 Sep 2024
At a glance
- Drugs Abetimus (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Acronyms ASPEN
- Sponsors La Jolla Pharmaceutical Company
- 09 Sep 2024 This trial has been completed in Hungary, according to European Clinical Trials Database record.
- 03 Oct 2013 Status changed from recruiting to discontinued as reported by Sri Lanka Clinical Trials Registry.
- 17 Sep 2011 New trial record